Guido Mieth By Marshall Gordon, Elisa Mazen and Charine Park Diabetes and Obesity Markets Large and Growing Drugs based on GLP-1 are developing into a mega blockbuster market for the treatment of diabetes and obesity. Danish pharmaceutical maker Novo Nordisk (NVO) has been involved for decades in the treatment of diabetes and is pioneering the advanced pharmaceutical treatment of obesity. ClearBridge initially purchased Novo in 2001, well ahead of the first clinical trials for its type 2 diabetes treatment ...